1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Aloxi (Palonosetron)
1.2.3 Kytril (Granisetron)
1.2.4 Emend (Aprepitant)
1.2.5 Others
1.3 Market by Application
1.3.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Acute Nausea and Vomitting Treatment
1.3.3 Delayed Nausea and Vomitting Treatment
1.3.4 Anticipatory Nausea and Vomitting Treatment
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Perspective (2017-2028)
2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Growth Trends by Region
2.2.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Region (2017-2022)
2.2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Region (2023-2028)
2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Dynamics
2.3.1 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends
2.3.2 Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers
2.3.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges
2.3.4 Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Revenue
3.1.1 Global Top Chemotheraphy-induced Nausea and Vomitting Treatment Players by Revenue (2017-2022)
3.1.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue
3.4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio
3.4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chemotheraphy-induced Nausea and Vomitting Treatment Revenue in 2021
3.5 Chemotheraphy-induced Nausea and Vomitting Treatment Key Players Head office and Area Served
3.6 Key Players Chemotheraphy-induced Nausea and Vomitting Treatment Product Solution and Service
3.7 Date of Enter into Chemotheraphy-induced Nausea and Vomitting Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chemotheraphy-induced Nausea and Vomitting Treatment Breakdown Data by Type
4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Type (2017-2022)
4.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Type (2023-2028)
5 Chemotheraphy-induced Nausea and Vomitting Treatment Breakdown Data by Application
5.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Application (2017-2022)
5.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2017-2028)
6.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2017-2022)
6.3 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2017-2028)
7.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2017-2022)
7.3 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2017-2028)
8.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2017-2022)
8.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2017-2028)
9.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2017-2022)
9.3 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2017-2028)
10.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2017-2022)
10.3 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Detail
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.1.4 GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.1.5 GlaxoSmithKline Recent Development
11.2 Helsinn
11.2.1 Helsinn Company Detail
11.2.2 Helsinn Business Overview
11.2.3 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.2.4 Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.2.5 Helsinn Recent Development
11.3 Heron Therapeutics
11.3.1 Heron Therapeutics Company Detail
11.3.2 Heron Therapeutics Business Overview
11.3.3 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.3.4 Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.3.5 Heron Therapeutics Recent Development
11.4 Merck & Co
11.4.1 Merck & Co Company Detail
11.4.2 Merck & Co Business Overview
11.4.3 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.4.4 Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.4.5 Merck & Co Recent Development
11.5 Tesaro
11.5.1 Tesaro Company Detail
11.5.2 Tesaro Business Overview
11.5.3 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.5.4 Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.5.5 Tesaro Recent Development
11.6 Acacia Pharma
11.6.1 Acacia Pharma Company Detail
11.6.2 Acacia Pharma Business Overview
11.6.3 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.6.4 Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.6.5 Acacia Pharma Recent Development
11.7 Aphios
11.7.1 Aphios Company Detail
11.7.2 Aphios Business Overview
11.7.3 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.7.4 Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.7.5 Aphios Recent Development
11.8 Barr Laboratories
11.8.1 Barr Laboratories Company Detail
11.8.2 Barr Laboratories Business Overview
11.8.3 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.8.4 Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.8.5 Barr Laboratories Recent Development
11.9 Baxter Healthcare
11.9.1 Baxter Healthcare Company Detail
11.9.2 Baxter Healthcare Business Overview
11.9.3 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.9.4 Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.9.5 Baxter Healthcare Recent Development
11.10 Eisai
11.10.1 Eisai Company Detail
11.10.2 Eisai Business Overview
11.10.3 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.10.4 Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.10.5 Eisai Recent Development
11.11 Especificos Stendhal
11.11.1 Especificos Stendhal Company Detail
11.11.2 Especificos Stendhal Business Overview
11.11.3 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.11.4 Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.11.5 Especificos Stendhal Recent Development
11.12 F.Hoffmann La Roche
11.12.1 F.Hoffmann La Roche Company Detail
11.12.2 F.Hoffmann La Roche Business Overview
11.12.3 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.12.4 F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.12.5 F.Hoffmann La Roche Recent Development
11.13 Mundipharma
11.13.1 Mundipharma Company Detail
11.13.2 Mundipharma Business Overview
11.13.3 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.13.4 Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.13.5 Mundipharma Recent Development
11.14 Mylan Pharmaceuticals
11.14.1 Mylan Pharmaceuticals Company Detail
11.14.2 Mylan Pharmaceuticals Business Overview
11.14.3 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.14.4 Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.14.5 Mylan Pharmaceuticals Recent Development
11.15 OPKO Health
11.15.1 OPKO Health Company Detail
11.15.2 OPKO Health Business Overview
11.15.3 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.15.4 OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.15.5 OPKO Health Recent Development
11.16 Orchid Healthcare
11.16.1 Orchid Healthcare Company Detail
11.16.2 Orchid Healthcare Business Overview
11.16.3 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
11.16.4 Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2017-2022)
11.16.5 Orchid Healthcare Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details